Breaking News Instant updates and real-time market news.
2018-10-02 12:56:53
XOM
Exxon Mobil
$86.63
0.8 (0.93%)
12:56
10/02/18
10/02
12:56
10/02/18
12:56
Exxon exploring possible sale of many U.S. Gulf of Mexico assets, Reuters says
11
Oct
XOMExxon Mobil
$86.63
0.8 (0.93%)
09/07/18
RHCO
09/07/18 UPGRADETarget $25 RHCO Buy
Centennial Resource Development upgraded to Buy at SunTrust on output prospects
As reported earlier, SunTrust analyst Neal Dingmann upgraded Centennial Resource Development (CDEV) to Buy from Hold and raised his price target to $25 from $20. The analyst cites the company's "operational strides" to ensure that its 2020 production goal is achieved while also noting its "pricing diversification" efforts through its latest crude agreement with Exxon Mobil (XOM) as well as its position of an "early mover" among Permian E&Ps on the gas side. Dingmann advises that investors take advantage of the current "opportune entry point" given Centennial Resource Development's "below peer valuation".
09/11/18
BREN
09/11/18 INITIATIONTarget $84 BREN Hold
Exxon Mobil initiated with a Hold at Berenberg
Berenberg analyst Henry Tarr started Exxon Mobil with a Hold rating and $84 price target.
09/21/18
RBCM
09/21/18 NO CHANGETarget $115 RBCM Outperform
Exxon Mobil long term investment visibility improving, says RBC Capital
RBC Capital analyst Biraj Borkhataria kept his Outperform rating and $115 price target on Exxon Mobil after meeting with its investor relations VP at the company's recent non deal roadshow. The analyst notes that the discussions focused on Exxon Mobil's accelerating rig activity in the Permian and Guyana with little impact observed from wider differentials. Borkhataria also believes that stock buybacks may begin as soon as early 2019, ahead of expectations, adding that the Exxon Mobil stock remains one of his "top ideas for longer term".
09/28/18
OPCO
09/28/18 NO CHANGETarget $89 OPCO Outperform
Teladoc price target raised to $89 from $68 at Oppenheimer
Oppenheimer analyst Mohan Naidu reiterated an Outperform rating on Teledoc and raised his price target to $89 from $68 following the company's analyst day, which highlighted its new deal flow, including relationships with Centene (CNC) and Exxon (XOM), and a very strong pipeline. The recent CMS telehealth proposal makes Medicare a 2020 tailwind, Naidu tells investors in a research note, and says he has gained confidence that Teladoc's competitive barriers include its broad platform and its network of physicians that quickly matches supply and demand.